Clinical Trials Browser

OTHER × Prostatic Neoplasms × Vinorelbine × Clear all

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT00003400 2019-11-04

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00003259 2019-06-26

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00003622 2017-07-13

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Phase 2 Withdrawn

Prostatic Neoplasms

NCT01155258 2016-06-13

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Completed

BreastCNSDermatologicEndocrineGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00151086 2015-01-22

Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms

NCT00278070 2008-02-29

Metronomic Oral Vinorelbine in Patients With Metastatic Tumors

Phase 2 Completed

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms